CRESCENT BIOPHARMA Business Summary

Crescent Biopharma, Inc. (CBIO) is a clinical-stage biotechnology company specializing in the development of precision-engineered molecules for the treatment of solid tumors. The company’s business model is centered on the research and development of high-impact oncology therapeutics, generating revenue primarily through strategic licensing agreements and milestone-based partnerships, such as its significant 2025 collaboration with Kelun-Biotech. Its primary business segments are divided into two innovative platforms: bispecific antibodies, led by its flagship PD-1 x VEGF candidate CR-001, and a robust pipeline of antibody-drug conjugates (ADCs), including CR-002 and CR-003. Crescent Biopharma competes directly with oncology-focused firms such as Summit Therapeutics, Akeso, Inc., and Rigel Pharmaceuticals; it distinguishes itself by targeting validated biological pathways with next-generation modalities designed to surpass the efficacy and safety profiles of current standards of care like pembrolizumab. The company is led by a high-pedigree executive team with extensive experience in scaling successful biotech ventures. Chief Executive Officer Joshua Brumm and President/COO Jonathan McNeill both joined in 2025 from Dyne Therapeutics, where they oversaw significant clinical advancements and capital raises. The clinical strategy is directed by Chief Medical Officer Dr. Ellie Im, a former clinical lead for Merck’s Keytruda, and Chief Scientific Officer Dr. Jan Pinkas, an ADC expert previously with Pyxis Oncology and ImmunoGen. Crescent was founded with backing from a syndicate of premier life sciences investors, including BVF Partners, Forbion, and Fairmount. The board is chaired by Peter Harwin, a managing member at Fairmount, reflecting a strong institutional foundation that supports the company’s aggressive clinical timeline through 2026 and beyond.